Products

EMARKETER delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
PRO+
New data sets, deeper insights, and flexible data visualizations.
Learn More
Reports
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Forecasts
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Charts
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Briefings
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About EMARKETER

Our goal is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Events
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Podcasts
Tune in to EMARKETER's daily, weekly, and monthly podcasts.
Learn More

Biofourmis bags $300M to mold itself into a digital health market leader

The news: Biofourmis scored $300 million in a Series D funding round led by General Atlantic.

  • It’s planning to use the funding to grow its virtual care offerings, including personalized and predictive home care solutions.
  • Biofourmis also plans to fund more clinical trials and improve its digital therapeutic (DTx). Its goal is to forge stronger partnerships with other digital health players.

Who is Biofourmis? Biofourmis started out as a DTx company, but later added a home care arm to its business. It was one of the earlier entrants in the hospital-at-home market.

How we got here: Biofourmis demonstrated its value and relevance in the digital health space in the last few years.

  • In December 2020, Biofourmis’ Biovitals Hospital@Home was one of the first hospital-at-home programs on the market. It partnered with Brigham and Women’s Hospital to launch the solution that uses remote patient monitoring (RPM) and AI to provide hospital-level care to patients in their homes.
  • In July 2021, it received the first ever FDA breakthrough device designation for a digital therapeutic for managing heart failure (BiovitalsHF).
  • And this past February, it launched Biofourmis Care—an AI-powered specialty care platform that uses RPM and virtual care to target chronic condition management.

Biofourmis also hits on two booming digital health markets: RPM and telehealth.

  • 15.1% of the US population (39.3 million people) used RPM in 2021. Insider Intelligence forecasts this will increase to 26.2% (70.6 million) by 2025, according to our RPM Users forecast.
  • In 2021, 36.1% of the US population (94.2 million people) used telehealth. We expect 43.3% of the US population (116.6 million people) to use the tech by 2025, per our Telehealth Users Forecast.

Why it’s worth watching: This is one of the biggest digital health funding rounds yet this year.

  • For example, some of the largest funding rounds recently include Reify Health’s $220M, NexHealth’s $125M, and Clarify Health’s $150M.

What’s next: Biofourmis is eyeing the value-based care (VBC) market, and we predict it will strike an M&A deal with a major payer to get there.

  • Value-based reimbursements have been slowly increasing since 2015, per The Healthcare Association of New York State’s analysis of national data from Health Care Payment Learning & Action.
  • Partnering with a payer would enable Biofourmis to become a part of more VBC contracts, while helping it expand its user base and business.